Exosome Skincare OEM China: Classification & Regulatory Status

In a February 2026 pre-order review at our Zhongshan facility, three of eleven exosome-themed briefs stalled at the same question: is this a cosmetic or something else? Under China's NMPA framework, exosome skincare OEM China cosmetic classification regulatory status hinges on listed ingredients, claims, and whether the finished product stays in the Cosmetic Supervision and Administration Regulation (CSAR) definition. Most exosome briefs fail not at formulation — they fail at ingredient listing and claim wording.

We've run over 40 eye-zone and patch SKUs through the same filing desk since 2023. The pattern repeats: the buyer assumes exosome equals active pharma, the formulator knows it does not, and the NMPA reviewer splits the difference by rejecting the claim, not the product (yes, that's the part buyers skip and regret later — the label text, not the formula).

What exosome skincare OEM China cosmetic classification regulatory status actually requires

Three gates. First, the ingredient. Plant-derived exosome-like vesicles (often marketed as "exosome extract") must be listed on IECIC — China's Inventory of Existing Cosmetic Ingredients — or filed as a new cosmetic ingredient, which adds 6–12 months and roughly ¥180,000–¥260,000 in safety data. Second, the claim. CSAR prohibits words that imply medical action: "repair," "regenerate," "heal," and "anti-inflammatory" are red flags. Third, the testing package. Ordinary cosmetics need microbial, heavy metal, and stability data; special cosmetics (sun protection, hair dye, whitening, acne) trigger a longer registration track of 4–7 months.

For most exosome briefs we route to ordinary cosmetic filing — a 5–8 working day record submission — provided the finished product does not contain human- or animal-derived exosomes. Those are not permitted as cosmetic ingredients in China and are a common failure point in briefs sourced from Korean marketing decks.

A practical shortlist when comparing OEM quotes:

• Confirm IECIC status of the exosome extract in writing before tooling.
• Ask for the ingredient's INCI name and CAS number — not the trade name.
• Require the formulator to sign off on label claims before artwork.
• Budget ¥35,000–¥60,000 per SKU for NMPA testing.

Crystal collagen eye mask OEM manufacturer China MOQ 3000 — how it fits the exosome brief

Buyers rarely come to us for a single SKU. A 2026 Q1 order from a Singapore brand paired an exosome eye serum with a hydrogel sheet mask line. The crystal collagen eye mask OEM manufacturer China MOQ 3000 threshold is where that pairing becomes economic — 3,000 pcs per SKU unlocks dedicated tooling, and below that the same mold is shared, adding 8–12 days of scheduling lag.

Crystal collagen eye masks are typically a hydrolyzed collagen gel cast — not a woven patch — and the cost structure differs from a serum. Per our 2025 production log:

Quote these against USD at the day's rate — the CNY swing in 2025 moved one quote by 4.7% between PO and deposit.

Silicone eye mask reusable OEM tooling cost China factory MOQ

Reusable silicone eye masks are a separate product class from hydrogel — no gel cast, but a compression mold. Silicone eye mask reusable OEM tooling cost China factory MOQ sits at 5,000 pcs for a new mold; existing molds drop the MOQ to 1,500. A single-cavity mold runs ¥18,000–¥24,000; a two-cavity, ¥32,000–¥38,000. Lifespan is roughly 500,000 shots before refurbishment.

For reusable products, add a labeling question: silicone eye masks with claims like "cooling" or "lymphatic" invite the same NMPA scrutiny as exosome serums. Keep claims mechanical — temperature, fit, reusability — and the filing stays ordinary.

Adjacent SKUs: acne patches and the LatAm route

If your exosome brief sits alongside a private label acne patch, our private label clay mask and acne patch lines run through the same QC bench. A U.S. buyer in March 2026 bundled four SKUs — an exosome serum, a crystal collagen eye mask, a hydrocolloid acne patch, and a silicone eye mask — into one tooling order and saved 22% against four separate POs. Consolidation is the cheapest optimization in this category.

FAQ

Q: Does an exosome serum sold as a cosmetic in China require NMPA registration or filing?

Filing, if the exosome source is a listed plant-derived ingredient and the claims stay cosmetic. Registration applies only to special cosmetics — sun protection, whitening, hair dye, acne — and takes 4–7 months versus 5–8 working days for ordinary filing.

Q: What is the crystal collagen eye mask OEM manufacturer China MOQ 3000 policy in practice?

3,000 pcs per SKU for dedicated tooling. Below 3,000, we run the SKU on a shared mold and add 8–12 days to the schedule. Above 10,000 pcs, per-unit FOB drops roughly 25–30% per our 2025 log.

Q: How much does silicone eye mask reusable OEM tooling cost at a China factory, and what MOQ applies?

A single-cavity compression mold costs ¥18,000–¥24,000; a two-cavity mold ¥32,000–¥38,000. MOQ is 5,000 pcs for a new mold, 1,500 pcs if a stock mold fits. Mold lifespan is about 500,000 shots.

Q: Can a Chinese OEM file the same exosome product for the EU and the U.S. at the same time?

Yes, and it's cheaper as a package. EU CPSR runs €1,800–€3,200; U.S. FDA does not pre-approve cosmetics but requires Voluntary Cosmetic Registration, which we handle at no extra fee when bundled with CPSR. Total timeline is 45–60 days.

Q: What testing package should accompany an exosome skincare OEM order from China?

Microbial, heavy metal, stability (3 months accelerated), and a challenge test if the formula contains water above 20%. Budget ¥35,000–¥60,000 per SKU and 28–45 days at an accredited lab such as SGS or Intertek.

Skincraftlab runs exosome, hydrogel, silicone, and hydrocolloid SKUs under one ISO 22716 and GMPC-certified roof in Zhongshan — which means one filing desk, one QC bench, and one consolidation PO across the whole eye-zone category.